Previous 10 | Next 10 |
Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, today announced the publication of a peer-reviewed case report analyzing the clinical outcomes of Zofin treatment in three criticall...
Organicell Regenerative Medicine (BPSR) announces that the U.S. FDA has approved the Investigational New Drug application for its lead product, Zofin, in the treatment of patients diagnosed with chronic obstructive pulmonary disease ((COPD)).The approved trial design will be a double bl...
Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced today that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for its...
A Live Online Discussion on COVID-19 Long-Haulers Hosted by Organicell Regenerative Medicine, Inc. Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR) (the “ Company ” or “ Organicell ”), a clinical-stage biopharmaceutical company d...
Organicell Regenerative Medicine, Inc. (OTCMKTS:BPSR) (the “ Company ”), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies today announced that the Company and its therapeutic drug Zofin™ were recently featured in ...
Organicell Regenerative Medicine, Inc. (OTCBB: BPSR) (the “ Company ”), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced that it is now current in its SEC reporting requirements under the Securities Exchange A...
The Phase number of the clinical trial in the first paragraph, first sentence of release should read: Phase I/II (instead of Phase I/I). The updated release reads: ORGANICELL ANNOUNCES ADDITIONAL SITE FOR PHASE I/II CLINICAL TRIAL OF ZOFIN™ FOR TREATMENT OF COVID-19 ...
Organicell Regenerative Medicine, Inc. (OTCBB: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced today that it is now enrolling patients at an additional site, Larkin Hospital North located in Hialeah, Florida for its Pha...
Organicell (BPSR) announces that several participants have been enrolled in its Phase 1/2 clinical trial evaluating Zofin in COVID-19 patients with moderate-to-severe acute respiratory distress syndrome. The subjects have been enrolled and treated at Larkin Hospital in Miami, FL.It expects to...
Anticipates Phase I/II trial completion by end of year Anticipates Phase IIb trial to begin in Q1 2021 Seeks to retain a global contract research organization (“CRO”) Organicell Regenerative Medicine, Inc. (OTCBB: BPSR), a clinical-stage biopharmaceutic...
News, Short Squeeze, Breakout and More Instantly...
Organicell Regenerative Medicine Inc Company Name:
BPSR Stock Symbol:
OTCMKTS Market:
Leading Therapeutics Research Company Begins New Era Common Stock to trade on OTCQB under the symbol "ZEOX" commencing March 5, 2024 FORT LAUDERDALE, FL / ACCESSWIRE / March 7, 2024 / ZEO ScientifiX, Inc . (OTCQB:ZEOX) (f/k/a Organicell Regenerative Medicine, Inc. - OTCQB:OCEL) today ...
Leading Therapeutics Research Company Begins New Era Common Stock to trade on OTCQB under the symbol "ZEOX" commencing March 5, 2024 FORT LAUDERDALE, FL / ACCESSWIRE / March 4, 2024 / ZEO ScientifiX, Inc . (OTCQB:ZEOX) (f/k/a Organicell Regenerative Medicine, Inc. - OTCQB: OCEL) today...
FORT LAUDERDALE, FL / ACCESSWIRE / November 27, 2023 / Organicell Regenerative Medicine Inc, (OTCQB:OCEL) ("Organicell" or the "Company"), today announced that it is implementing a 1-for-200 Reverse Split of the Company's common stock (the "Reverse Split") effective as of the close of business o...